Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Abstract: Disclosed is a pharmaceutical composition for treating chronic obstructive pulmonary disease, comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method for treating chronic obstructive pulmonary disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent.

Abstract: Disclosed is a pharmaceutical composition for treating ischemic stroke, comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method for treating ischemic stroke in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent. In addition, a method for promoting secretion of hepatocyte growth factor by human mesenchymal stem cells is disclosed.

Abstract: Disclosed is a method for identifying a greater risk for developing bronchopulmonary dysplasia (BPD) of a preterm infant. The method comprises obtaining a genomic DNA sample from the preterm infant's mother, genotyping rs1800566 SNP in the NQO1 gene, and determining the preterm infant as being at risk of developing BPD if the genotype of the rs1800566 SNP is TT. Also disclosed are a primer pair for genotyping rs1800566 SNP in the NQO1 gene, and a method thereof.

Abstract: Disclosed is a method for identifying a greater risk for developing bronchopulmonary dysplasia (BPD) of a preterm infant. The method comprises obtaining a genomic DNA sample from the preterm infant's mother, genotyping rs2280789 SNP in the RANTES gene, and determining the preterm infant as being at risk of developing BPD if the genotype of the rs2280789 SNP is CC. Also disclosed are a primer pair for genotyping rs2280789 SNP in the RANTES gene, and a method thereof.

Abstract: Disclosed is a method of identifying a greater risk for developing bronchopulmonary dysplasia (BPD) in a preterm infant. The method comprises obtaining a genomic DNA sample from the preterm infant's mother, identifying the nucleotide of rs2280789 SNP in the RANTES gene and the nucleotide of rs1800566 SNP in the NQO1 gene, and determining the preterm infant as being at risk of developing BPD when the genotype of rs2280789 SNP carries C nucleotide and the genotype of rs1800566 SNP carries T nucleotide.

Abstract: Provided is a method for determining the risk of preterm labor in a pregnant female subject. The method comprises detecting the expression level of one or more markers selected from the group consisting of TMEM200A, TMEM108 and GXYLT2, in a sample derived from the pregnant female subject.

Abstract: Provided is a method for determining the risk of bronchopulmonary dysplasia (BPD) of a preterm infant. The method comprises detecting the expression level of EPHB2 in a primary culture of mesenchymal stem or stromal cells (MSCs) derived from a placenta-related tissue of the infant's mother or umbilical cord blood of the infant.

Abstract: A method of distinguishing mesenchymal stem cells (MSCs) from fibroblasts is provided. Also provided is a method of increasing a purity of mesenchymal stem cells (MSCs) population in a cell culture. The above-mentioned methods each comprise a step of sorting or isolating the cells by a marker of CD146 from a cell culture derived from a placenta-related tissue. Further provided is a method of assessing purity of mesenchymal stem cells (MSCs) in a cell culture derived from a placenta-related tissue, comprising determining the percentage of cells expressing CD146 in the culture.

Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.

Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.